GlassScriptPhysician profile
Melissa L Brown
NPI 1346923596
$4,586.88
in general payments reported to CMS, 2019-2025
23 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $317 · 2024: $1,206 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,575 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,575.01 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.34 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $578.95 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $472.75 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $433.18 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $373.06 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $372.06 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $279.94 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.69 | 2024-2025 | Caplyta |
| Corium, LLC | $144.04 | 2024-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2023 | Xifaxan |
| Jazz Pharmaceuticals INC. | $110.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.14 | 2025 | Trintellix |
| Silk Road Medical, INC. | $75.92 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Collegium Pharmaceutical, INC. | $74.83 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $74.82 | 2024-2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $43.87 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $42.38 | 2024-2025 | Qelbree |
| Indivior INC. | $24.15 | 2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $22.57 | 2025 | Quviviq |
| Janssen Pharmaceuticals, INC | $21.76 | 2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $19.97 | 2024 | |
| Convatec INC. | $19.84 | 2024 | |
| Novo Nordisk INC | $13.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.